Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled ... for patients who pay with cash at $35 per monthly prescription, regardless of whether the patients have insurance.

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

If you are interested in using PlushCare, you must sign up for a subscription ... In August 2024, Eli Lilly announced that Zepbound would be available on its online pharmacy, LillyDirect ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

I recently learned of Eli Lilly ... the shortage of Lilly’s blockbuster GLP-1, tirzepatide (brand names, Mounjaro® and Zepbound®), as well as stoppage dates for compound pharmacies and ...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics ...

It was a bad day for Eli Lilly, the world’s biggest drug maker ... It’s probably just a bump in the path higher rather than a sign that demand is tepid. It’s worth remembering that even ...

In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic response at one year Among those who achieved clinical ...

Eli Lilly has raised its ... The strong growth for Lilly's tirzepatide products came after market leader Novo Nordisk reported the first signs of weaker growth for its rival semaglutide products ...